1. Injectable form of 5α-androstan-3β, 5,6β-triol, including a liquid injectable form containing a solvent, or a solid injectable form containing at least one soluble excipient, wherein said at least one soluble excipient comprises hydroxypropyl- β-cyclodextrin. 2. The injection form according to claim 1, characterized in that 5α-androstan-3β, 5,6β-triol is present in a mass ratio of 1 ~ 20: 40 ~ 500 to hydroxypropyl-β-cyclodextrin. The injection form according to claim 1 or 2, characterized in that the soluble excipient further comprises an isotonicity regulating agent and / or a freeze-drying filler. The injection form according to claim 3, characterized in that the isotonicity regulating agent is selected from the group consisting of sodium chloride, glucose, mannitol, lactose, xylitol, sorbitol, maltitol and mixtures thereof. 5. The injection form according to claim 3, characterized in that the filler for freeze-drying is selected from the group consisting of sodium chloride, glucose, mannitol, lactose, xylitol, sorbitol, maltitol and mixtures thereof. 6. The injection form according to claim 1 or 2, characterized in that the solvent for the liquid injection form is selected from the group consisting of propanediol, ethanol, polyethylene glycol 400, polyethylene glycol 200, glycerol, water and mixtures thereof. 7. The injection form according to claim 3, characterized in that said injection form consists of (by weight): 1 ~ 20 parts of 5α-androstan-3β, 5,6β-triol, 4 ~ 500 parts of hydroxypropyl-β-cyclodextrin, 1 ~ 100 parts of an isotonicity regulating agent, 0 ~ 200 parts of a freeze-drying filler, and 0 ~ 2000 parts of a solvent. 8. A method of obtaining an injection form according to claim 11. Инъекционная форма 5α-андростан-3β,5,6β-триола, включая жидкую инъекционную форму, содержащую растворитель, или твердую инъекционную форму, содержащая по меньшей мере одно растворимое вспомогательное вещество, причем указанное по меньшей мере одно растворимое вспомогате
